Platelet Activation and Reactivity in Acute Exacerbations of COPD
Overview
Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of cardiovascular disease. Platelets contribute to acute cardiovascular events and atherosclerosis. When platelets are activated, they form complexes with monocytes. These platelet-monocyte complexes (PMCs) are an early process in atherothrombosis and promote inflammation. In COPD, platelet function in AE-COPD is scarcely studied. This study aims to address this gap by investigating platelet function and coagulation in patients with AE-COPD and after convalescence.
Full Title of Study: “Platelet Activation and Responsiveness in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 2017
Interventions
- Other: Blood is drawn
- Blood analyses
Clinical Trial Outcome Measures
Primary Measures
- Platelet activation: platelet expression of CD62P (P-selectin) and fibrinogen binding at baseline and upon ex vivo stimulation.
- Time Frame: Measured at presentation with an AE-COPD and after 8 weeks
Secondary Measures
- Platelet-monocyte interaction (CD14 cells positive for CD61)
- Time Frame: Measured at presentation with an AE-COPD and after 8 weeks
- Monocyte activation (CD11b expression on CD14 positive cells)
- Time Frame: Measured at presentation with an AE-COPD and after 8 weeks
- Tissue factor triggered thrombin generation capacity
- Time Frame: Measured at presentation with an AE-COPD and after 8 weeks
- Plasma markers: Interleukin-6, Interleukin-8, high sensitive-CRP, soluble P-selectin, soluble Fibrinogen, D-dimer
- Time Frame: Measured at presentation with an AE-COPD and after 8 weeks
Participating in This Clinical Trial
Inclusion Criteria
- >40 years – Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC < 70% and less than 12% on reversibility testing< Lower limit of normal (LLN)) – ≥10 pack years of smoking Exclusion Criteria:
- Use of anti-coagulation or other platelet function inhibitors – Asthma – Chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE) – Malignancies
Gender Eligibility: All
Minimum Age: 40 Years
Maximum Age: 99 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Radboud University Medical Center
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Yvonne F Heijdra, Md, PhD, Principal Investigator, Radboud University Medical Center
- Overall Contact(s)
- Floor E Aleva, MD, 0031 24 361 03 25, floor.aleva@radboudumc.nl
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.